SCOTTS VALLEY, Calif.,
June 16, 2021 /PRNewswire/
-- Dovetail Genomics, the industry leader in advanced
proximity ligation genomic solutions, today announced
availability of its new line of capture
Hi-C technology. The flagship products include two
targeted enrichment panels, the
Dovetail® Human Pan Promoter Enrichment
Kit, and the Dovetail® Mouse Pan Promoter
Enrichment Kit, enabling the interrogation of chromatin
topology surrounding 80,000 coding and non-coding gene
promoters for human and mouse
samples respectively. Dovetail's solution incorporates Twist
Bioscience's (Nasdaq: TWST) proprietary targeted
enrichment technology and is matched
with Dovetail's unique Micro-C
and Omni-C® Assays, each of which utilize
sequence-independent nucleases for superior coverage compared to
restriction enzyme-based Hi-C methodologies.
Genome-wide Hi-C studies have been highly informative in
defining the critical relationship between chromosome
architecture and gene expression. However, the
sequencing depth required can be
a significant barrier to larger studies.
Dovetail's new products reduce the sequencing burden
by over 90%, enabling interactions between promoters and
their regulatory elements to be studied at a fraction of the cost.
In addition, the targeted approach
increases the sensitivity and resolution of the assay.
Taken together, these benefits make this approach ideal for a
broad variety of research questions
including larger translational studies, opening the
potential for discovery of a new class of chromatin topology-based
biomarker.
Emily Leproust, Ph.D., CEO and co-founder of Twist
Bioscience, stated, "We are thrilled to be
collaborating with
Dovetail Genomics to bring Twist's innovative targeted
enrichment technology to new markets. With our incredibly
flexible target enrichment design capabilities and precise DNA
synthesis, Dovetail is developing new and
innovative panels to advance the study of chromatin
topology."
"The ability of regulatory elements to act across large
genomic distances has long been known
and, through chromatin conformation
capture techniques, the looping events that bring
promoters and their regulatory elements, such
as transcriptional enhancers, into close
proximity are just starting to be probed," said Todd
Dickinson, CEO. "Our new
panels now enable these experiments to be
completed at a fraction of the cost of genome-wide Hi-C
approaches. This opens up
avenues for translational research that rely
on larger sample cohorts. In working with Twist, we are
confident that these new best-in-class
tools will help to accelerate understanding
of human disease mechanisms, aid in drug discovery
programs and offer a novel and valuable class
of biomarker benefiting human disease diagnosis and
management."
About Dovetail Genomics
Dovetail Genomics LLC is transforming genomics by making long-range
information readily accessible to all. The company enables
researchers and clinicians to solve complex problems
involving de novo assembly, structural variation,
chromatin epigenetics and topology analysis, cancer research,
chromosome-scale phasing, and more by providing them a more
comprehensive view of the genome. With 68 pending applications and
14 issued patents, its proprietary in
vitro proximity ligation approach and assembly algorithms
simplify genomic discovery by integrating the highest quality
long-range genomic information with next-generation sequencing
output. Dovetail is based in Scotts Valley, California. For more
information on Dovetail, its technology, and service offerings,
visit https://dovetailgenomics.com/targetedenrichment/. Follow
Dovetail on Twitter @DTGenomics.
About Twist Bioscience Corporation
Twist
Bioscience is a leading and rapidly growing synthetic biology and
genomics company that has developed a disruptive DNA synthesis
platform to industrialize the engineering of biology. The core of
the platform is a proprietary technology that pioneers a new method
of manufacturing synthetic DNA by "writing" DNA on a silicon chip.
Twist is leveraging its unique technology to manufacture a broad
range of synthetic DNA-based products, including synthetic genes,
tools for next-generation sequencing (NGS) preparation, and
antibody libraries for drug discovery and development. Twist is
also pursuing longer-term opportunities in digital data storage in
DNA and biologics drug discovery. Twist makes products for use
across many industries including healthcare, industrial
chemicals, agriculture and academic research.
Follow us on Twitter | Facebook | LinkedIn | YouTube
Legal Notice Regarding Forward-Looking Statements
This press release contains forward-looking statements. All
statements other than statements of historical facts contained
herein, including but not limited to the ability of Dovetail
Genomics' new line of capture Hi-C technology to effectively
address a broad variety of research questions, including larger
translational studies, to open the potential for discovery of a new
class of chromatin topology-based biomarker, to advance the study
of chromatin topology, to accelerate understanding of human disease
mechanisms, to aid in drug discovery programs and to offer a novel
and valuable class of biomarker benefiting human disease diagnosis
and management, are forward-looking statements reflecting the
current beliefs and expectations of management made pursuant to the
safe harbor provisions of the Private Securities Litigation Reform
Act of 1995. Such forward-looking statements involve known and
unknown risks, uncertainties, and other important factors that may
cause Twist Bioscience's actual results, performance, or
achievements to be materially different from any future results,
performance, or achievements expressed or implied by the
forward-looking statements. Such risks and uncertainties include,
among others, the risks and uncertainties of the ability to attract
new customers and retain and grow sales from existing customers;
risks and uncertainties of rapidly changing technologies and
extensive competition in synthetic biology could make the products
Twist Bioscience is developing obsolete or non-competitive;
uncertainties of the retention of a significant customer; risks of
third party claims alleging infringement of patents and proprietary
rights or seeking to invalidate Twist Bioscience's patents or
proprietary rights; and the risk that Twist Bioscience's
proprietary rights may be insufficient to protect its technologies.
For a further description of the risks and uncertainties that could
cause actual results to differ from those expressed in these
forward-looking statements, as well as risks relating to Twist
Bioscience's business in general, see Twist Bioscience's risk
factors set forth in Twist Bioscience's Quarterly Report Form 10-Q
filed with the Securities and Exchange Commission on May 7, 2021 and subsequent filings with the SEC.
Any forward-looking statements contained in this press release
speak only as of the date hereof, and Twist Bioscience specifically
disclaims any obligation to update any forward-looking statement,
whether as a result of new information, future events or
otherwise.
View original
content:http://www.prnewswire.com/news-releases/dovetail-genomics-announces-new-capture-hi-c-targeted-enrichment-panels-301313465.html
SOURCE Dovetail Genomics LLC